Cybin Inc. (OTCMKTS:CYBN – Get Free Report) fell 5.7% during mid-day trading on Monday . The company traded as low as $6.20 and last traded at $6.34. 269,681 shares changed hands during trading, an increase of 3% from the average session volume of 261,761 shares. The stock had previously closed at $6.72.
Cybin Price Performance
The firm has a market cap of $136.16 million, a P/E ratio of -33.37 and a beta of 0.50. The firm’s 50 day moving average is $8.51 and its 200 day moving average is $9.17.
About Cybin
Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.
Further Reading
- Five stocks we like better than Cybin
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- 3 Buyable Stocks With Solid Bottoms Ready to Rebound
- Election Stocks: How Elections Affect the Stock Market
- Advantage+ Shopping: Meta’s Fast Growing $20 Billion AI-Ads Star
- Conference Calls and Individual Investors
- Robotaxi News: What Tesla and Lyft Headlines Mean for Shares
Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.
